Dr. Raquibul Hannan
Claim this profileECOG-ACRIN Cancer Research Group
Studies Cancer
Studies Renal Cell Carcinoma
2 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials Raquibul Hannan is currently running
Stereotactic Radiation + Immunotherapy
for Kidney Cancer
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
Recruiting1 award Phase 221 criteria
Focused Radiation vs Systemic Therapy
for Kidney Cancer
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in the body (metastatic). Study doctors want to find out if this approach is better or worse than the usual approach for metastatic kidney cancer. The usual approach is defined as the care most people get for metastatic kidney cancer which includes systemic therapy such as immunotherapy (given through the veins) and/or small molecular inhibitor (tablets taken by mouth). Radiotherapy uses high energy x-rays to kill cancer cells and shrink tumors. SAbR uses special equipment to position a patient and deliver radiation to tumors with high precision. Giving SAbR prior to systemic therapy may kill more tumor cells than the usual approach, which is systemic therapy alone.
Recruiting2 awards Phase 319 criteria
More about Raquibul Hannan
Clinical Trial Related2 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Raquibul Hannan has experience with
- Stereotactic Ablative Radiotherapy
- Systemic Therapy
- Avelumab
- Axitinib
- Cabozantinib
- Ipilimumab
Breakdown of trials Raquibul Hannan has run
Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Raquibul Hannan specialize in?
Raquibul Hannan focuses on Cancer and Renal Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Raquibul Hannan currently recruiting for clinical trials?
Yes, Raquibul Hannan is currently recruiting for 2 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Raquibul Hannan has studied deeply?
Yes, Raquibul Hannan has studied treatments such as Stereotactic Ablative Radiotherapy, Systemic Therapy, Avelumab.
What is the best way to schedule an appointment with Raquibul Hannan?
Apply for one of the trials that Raquibul Hannan is conducting.
What is the office address of Raquibul Hannan?
The office of Raquibul Hannan is located at: ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania 19103 United States. This is the address for their practice at the ECOG-ACRIN Cancer Research Group.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.